Change in quality of life after medical and surgical treatment of graves ophthalmopathy

Middle East African Journal of Ophthalmology

Volumn 18, Issue 1, 2011, Pages 42-47

  Kashkouli, Mohsen Bahmani ^a   Heidari, Iraj ^b   Pakdel, Farzad ^a   Jam, Sara ^a   Honarbakhsh, Yasamin ^a   Mirarmandehi, Bahareh ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Eyelid Retraction; Graves Ophthalmopathy; Proptosis; Quality of Life

Indexed keywords

STEROID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENDOCRINE OPHTHALMOPATHY; EYE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DECOMPRESSION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT COUNSELING; PATIENT EDUCATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SOCIAL PSYCHOLOGY; THYROID DISEASE;

EID: 79953067136     PISSN: 09749233     EISSN: 09751599     Source Type: Journal    
DOI: 10.4103/0974-9233.75884     Document Type: Article

References (23)

1. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves ophthalmopathy: The GO-QOL. Br J Ophthalmol 1998;82:773-9. (Pubitemid 28376907)
2. Park JJ, Sullivan TJ, Mortimer RH, Wagenaar M, Perry-Keene DA. Assessing quality of life in Australian patients with Graves ophthalmopathy. Br J Ophthalmol 2004;88:75-8. (Pubitemid 38091368)
3. Wiersiga WM, Bartalena L. Epidemiology and prevention of GO. Thyroid 2002;12:855-60.
4. Rootman J. Diseases of the orbit, a multi-disciplinary approach. Thyroid Orbitopathy. 2 nd ed. Philadelphia
5. Farid M, Roch-Levecq AC, Levi L, Brody BL, Granet DB, Kikkawa DO. Psychological disturbance in graves ophthalmopathy. Arch Ophthalmol 2005;123:491-6. (Pubitemid 40489920)
6. Prez Moreiras JV, Coloma Bockos JE, Prada Sanchez MC. Thyroid orbitopathy (pathogenesis, diagnosis, and treatment). Arch Soc Esp Oftalmol 2003;78:407-31.
7. Wilsone IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995;273:59-65.
8. Kahaly GJ, Hardt J, Petrak F, Egle UT. Psychosocial factors in subjects with thyroid-associated ophthalmopathy. Thyroid 2002;12:237-9. (Pubitemid 34259806)
9. Elberling TV, Rasmussen AK, Feldt-Rasmussen U, Hørding M, Perrild H, Waldemar G. Impaired health-related quality of life in Graves disease. A prospective study. Eur J Endocrinol 2004;151:549-55. (Pubitemid 39562508)
10. Testa MA, Simonson DC. Assessment of quality of life outcomes. N Engl J Med 1996;334:835-40.
11. Prummel MF, Wiersinga WM. Smoking and risk of Graves disease. JAMA 1993;269:479-82.
12. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in Graves ophthalmopathy is markedly reduced: Measurement by the medical outcomes study instrument. Thyroid 1997;7:885-9. (Pubitemid 28041663)
13. Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989;262:907-13. (Pubitemid 19208947)
14. de Boer AG, Wijker W, Bartelsman JF, de Haes HC. Inflammatory bowel disease questionnaire: Cross-cultural adaptation and further validation. Eur J Gastroenterol Hepatol 1995;7:1043-50. (Pubitemid 26014459)
15. Terwee CB, Gerding MN, Dekker FW, Prummel MF, van der Pol JP, Wiersinga WM, et al. Test-retest reliability of the GO-QOL: A disease-specific quality of life questionnaire for patients with Graves ophthalmopathy. Br J Ophthalmol 2004;88:75-8.
16. Werner SC. Modification of the classification of the eye changes of Graves disease. Am J Ophthalmol 1977;83:725-7. (Pubitemid 8136099)
17. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves ophthalmopathy: A novel approach. Br J Ophthalmol 1989;73:639-44. (Pubitemid 19202075)
18. Jaeshke R, Singer J, Guvatt GH. Measurements of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:104-15.
19. Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, et al. Interpretation and validity of changes in scores on the Graves ophthalmopathy quality of life questionnaire (GO-QOL) after different treatment. Clin Endocrinol (Oxf) 2001;54:391-8. (Pubitemid 32234205)
20. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, et al. Long term follow up of Graves ophthalmopathy in an incidence cohort. Ophthalmology 1996;103:958-62. (Pubitemid 26190733)
21. Wiersinga WM, Prumnel MF, Terwee CB. Effects of Graves ophthalmopathy on quality of life. J Endocrinol Invest 2004;27:259-64. (Pubitemid 38607479)
22. Alonso J, Ant JM, Gonzlez M, Fiz JA, Izquierdo J, Morera J. Measurement of general health status of non-oxygen-dependent chronic obstructive pulmonary disease patients. Med Care 1992;30:MS125-35.
23. Peterson WL, Sturdevant RA, Frankl HD, Richardson CT, Isenberg JI, Elashoff JD, et al. Healing of duodenal ulcer with an antacid regimen. N Engl J Med 1977;297:341-5. (Pubitemid 8140359)